You might remember this post from July of 2011, from a meta-analysis in JAMA showing that the risk of new onset diabetes was higher in the intensive dose group, at 1.12. Now there’s another review from Women’s Health Initiative data suggesting a similar theory.
The Women’s Health Initiave, oft shortened to WHI, looked at over 161,00 women between 1993 to 1998, and followed up the data for several years, with this analysis going until 2005. It was most famous for highlighting the adverse effects of HRT, from thrombosis to malignancy – and now it’s finding a problem with statins.
The risk at baseline of diabetes mellitus was 1.71, and remained after doing multivariate analysis to exclude for other identified confounders (1.48). It’s certainly interesting – such beneficial pleitropic cardiovascular effects, and yet the possibility to unleash a a major cardiovascular risk factor.
Could you do a randomised controlled trial however? Perhaps in the field of primary prevention, but when it comes to secondary prevention, where the majority of evidence is, ethics approval could be tricky.